Forest Lab Settles Bystolic Patent Row With Generic Drugmaker
Pharmaceutical company Forest Laboratories Inc. said Friday it had agreed to drop patent infringement claims against generic drugmaker Hetero Labs Ltd. over the beta-blocker Bystolic after the two reached a licensing...To view the full article, register now.
Already a subscriber? Click here to view full article